Adam Walsh
Stock Analyst at Roth MKM
(3.96)
# 1,830
Out of 4,703 analysts
138
Total ratings
44.8%
Success rate
9.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Adam Walsh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EQ Equillium | Reiterated: Buy | $12 | $2.21 | +442.99% | 12 | Sep 4, 2026 | |
| ARCT Arcturus Therapeutics Holdings | Rated: Buy | $20 → $41 | $15.82 | +159.17% | 9 | Sep 2, 2026 | |
| OSTX OS Therapies | Reiterated: Buy | $7 | $1.88 | +272.34% | 2 | Aug 18, 2026 | |
| INSM Insmed | Reiterated: Buy | $212 | $126.29 | +67.87% | 22 | Aug 7, 2026 | |
| VTVT vTv Therapeutics | Reiterated: Buy | $58 | $33.35 | +73.91% | 6 | Aug 7, 2026 | |
| BIOA BioAge Labs | Maintained: Buy | $25 | $9.59 | +160.69% | 4 | Aug 7, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintained: Buy | $70 → $82 | $15.30 | n/a | 19 | May 18, 2020 | |
| ASND Ascendis Pharma | Reiterated: Buy | $81 → $171 | $270.56 | n/a | 3 | Apr 20, 2020 | |
| LKFT Lakefront Biotherapeutics NV | Maintained: Buy | $298 | $28.49 | n/a | 9 | Apr 8, 2020 | |
| CORT Corcept Therapeutics | Maintained: Hold | n/a | $111.62 | n/a | 8 | Feb 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $71 | $8.55 | n/a | 2 | Nov 12, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $36 → $25 | $1.48 | n/a | 4 | Jun 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $11 → $17 | $145.72 | n/a | 3 | May 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 | $3.88 | n/a | 3 | Nov 5, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $129 → $182 | $546.12 | n/a | 13 | Jul 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $105 → $107 | $66.53 | n/a | 5 | Mar 3, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $221.37 | $9.06 | n/a | 1 | Nov 30, 2015 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $160 | $266.11 | n/a | 11 | Jun 24, 2015 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $16 → $30 | $22.50 | n/a | 2 | May 20, 2015 |
Equillium
Sep 4, 2026
Reiterated: Buy
Price Target: $12
Current: $2.21
Upside: +442.99%
Arcturus Therapeutics Holdings
Sep 2, 2026
Rated: Buy
Price Target: $20 → $41
Current: $15.82
Upside: +159.17%
OS Therapies
Aug 18, 2026
Reiterated: Buy
Price Target: $7
Current: $1.88
Upside: +272.34%
Insmed
Aug 7, 2026
Reiterated: Buy
Price Target: $212
Current: $126.29
Upside: +67.87%
vTv Therapeutics
Aug 7, 2026
Reiterated: Buy
Price Target: $58
Current: $33.35
Upside: +73.91%
BioAge Labs
Aug 7, 2026
Maintained: Buy
Price Target: $25
Current: $9.59
Upside: +160.69%
Ultragenyx Pharmaceutical
May 18, 2020
Maintained: Buy
Price Target: $70 → $82
Current: $15.30
Upside: n/a
Ascendis Pharma
Apr 20, 2020
Reiterated: Buy
Price Target: $81 → $171
Current: $270.56
Upside: n/a
Lakefront Biotherapeutics NV
Apr 8, 2020
Maintained: Buy
Price Target: $298
Current: $28.49
Upside: n/a
Corcept Therapeutics
Feb 10, 2020
Maintained: Hold
Price Target: n/a
Current: $111.62
Upside: n/a
Nov 12, 2019
Maintained: Buy
Price Target: $71
Current: $8.55
Upside: n/a
Jun 25, 2019
Maintained: Buy
Price Target: $36 → $25
Current: $1.48
Upside: n/a
May 8, 2019
Upgraded: Buy
Price Target: $11 → $17
Current: $145.72
Upside: n/a
Nov 5, 2018
Maintained: Buy
Price Target: $35
Current: $3.88
Upside: n/a
Jul 18, 2017
Rated: Buy
Price Target: $129 → $182
Current: $546.12
Upside: n/a
Mar 3, 2016
Reiterated: Buy
Price Target: $105 → $107
Current: $66.53
Upside: n/a
Nov 30, 2015
Initiated Coverage: Buy
Price Target: $221.37
Current: $9.06
Upside: n/a
Jun 24, 2015
Maintained: Buy
Price Target: $160
Current: $266.11
Upside: n/a
May 20, 2015
Upgraded: Buy
Price Target: $16 → $30
Current: $22.50
Upside: n/a